Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seagen

Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.

Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets

Sanofi will give its shareholders the opportunity to be part of EUROAPI's new chapter of growth through an additional extraordinary dividend in kind

Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris

Sanofi (SNY) is developing a subcutaneous formulation of its myeloma drug, Sarclisa. A pivotal study is expected to start in the second half of 2022.

Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa

Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.

Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in the Phase 2 AMEERA-3 trial. Results from the Phase 2 trial showed that the drug amcenestrant, given as a pill, did not.

Why Sanofi Shares Are Trading Lower Today

Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Sanofi shares drop on trial setback for breast cancer pill

Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer

Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A

Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints

Sanofi (SNY) Management Presents at Cowen 42nd Annual Healthcare Conference (Transcript)

Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated severe hemophilia A patients aged 12 and above. The study met the primary endpoint, showing.

Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of bleeding episodes, showing a statistically significant and clinically meaningful reduction in annualised bleeding rate compared to prior factor VIII prophylaxis therapy Efanesoctocog alfa is a novel and investigational factor VIII therapy designed to provide near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen STOCKHOLM, March 9, 2022 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and Sanofi (EURONEXT: SAN and NASDAQ: SNY) today announced positive top-line results from the pivotal XTEND-1 phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001) in previously treated patients ≥12 years of age with severe haemophilia A. The study met the primary endpoint, showing a clinically meaningful prevention of bleeds in people with severe haemophilia A receiving weekly prophylaxis with efanesoctocog alfa over a period of 52 weeks.

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Sanofi recognized by S&P as one of the most sustainability-committed companies

Arbor Realty Trust

Amcor Plc

Ares Management

Franklin Resources

Enterprise Products Partners

Innovative Industrial Properties

Kinder Morgan

Leggett & Platt

Main Street Capital

Magellan Midstream Partners

Pembina Pipeline

People's United Financial

Philip Morris

Starwood Property

T. Rowe Price Group

Unilever

On February 2, 2022, A Kiplinger Today special report featured "Potent Picks to Profit in 2022." This article features 98 dividend-fetching stocks from YCharts 3/4/22 data.

Potent Picks To Profit 2022 Peg 11 Ideal March Dividend Buys

AstraZeneca

Bristol-Myers

Eli Lilly

Pfizer

Can these health care stocks climb this month?

5 Health Care Stocks To Watch In March 2022

Amgen

CVS Health

These three stocks are solid value picks in different areas of healthcare.

3 Top Healthcare Stocks to Buy for March

AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.

AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections

Adagene

Sanofi SA (NASDAQ: SNY) has signed a collaboration with Adagene Inc (NASDAQ: ADAG) to advance two preclinical immuno-oncology candidates and an option to develop two more.  Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones.

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

Shares of Adagene Inc. ADAG, +1.10% jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi SNY, -2.65% that is worth up to $2.5 billion. U.S.-listed shares of Sanofi were down 1.5%.

Sanofi to pay up to $2.5 billion in deal with Adagene

GlaxoSmithKline

GlaxoSmithKline PLC (LSE:GSK) and Sanofi SA said they plan to submit data from their booster and Phase III trials as a basis for their regulatory applications for a COVID-19 vaccine. The companies are in talks with regulatory authorities, including the US Food & Drug Administration and the European Medicines Agency.

GlaxoSmithKline and Sanofi plan to submit data from COVID-19 booster and Phase III trials for approval

Sanofi SA SNY, -0.80% and GlaxoSmithKline PLC GSK, -0.81% said Wednesday that their jointly-developed coronavirus vaccine has shown positive results in final-stage clinical trials and that they intend to seek regulatory approval for the shot.

Dow Jones Newswires: Sanofi, GSK to seek approval for Covid-19 vaccine after positive trial results

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Sanofi's Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Consider Sanofi (SNY) Stock Now?

Regeneron Pharmaceuticals

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU). The trial included CSU patients who don't respond to biologic treatment, Novartis AG (NYSE: NVS) / Roche Holdings AG's (OTC: RHHBY) Xolair (omalizumab).

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

AbbVie

Vertex Pharmaceuticals

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

News for Sanofi Stock (SNY)